๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Randomized trial comparing three different regimens of interferon alfa 2a in chronic hepatitis C

โœ Scribed by M Angelico


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
109 KB
Volume
23
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


small numbers of HCC cells may be released into the man research review committee. Informed consent had been obtained from the patients involved. circulation, be it spontaneously or induced by surgical

The results show that albumin mRNA can be demanipulation. Based on their findings, the authors sugtected in central as well as peripheral blood samples gest that, indeed, circulating tumor cells are present collected after, but not before, recipient hepatectomy. in the peripheral circulation as indicated by the PCR A semiquantitive analysis, as expressed by log mRNA technique.

equivalents per milliliter of blood, reveals identical We believe that the outcome of their experiments amounts of albumin expression in blood samples colshould be interpreted more cautiously. As mentioned lected at the indicated time points within the first 24 by Carr in an editorial on this subject in 1994, the hours. Because histological examination of the hepatecassay does not actually measure cancer cells. 2 Thus, tomized livers confirmed the absence of any maligthe mRNA-PCR technique identifies a liver-specific cell nancy, we conclude that positive results of an albumin marker that also may indicate the presence of nontu-mRNA test as such has no predictive value for the presmoral hepatic cells in the circulation. However, because ence of HCC. It may well be that hepatocytes, which the authors only found a positive PCR signal for albuare released into the circulation by surgical manipulamin mRNA in isolated cells from the peripheral blood tion or by reperfusion, are the origin of the albumin of patients with advanced-stage HCC, they speculated mRNA. that it was a result of the presence of malignant cells.

Our findings of positive results of an albumin mRNA The authors did not mention the time points at which assay in patients without a malignancy are in accorblood samples were obtained. The results of our studies dance with the report or Matsumura et al., 3 who using the same technique to detect albumin mRNA showed the presence of albumin mRNA in peripheral within the first 24 hours after liver transplantation blood of normal volunteers. Their results and those of show different results and cast doubt on the value of our study indicate that the consequences of positive this assay as a method to identify the presence of maligassay results for albumin mRNA should be interpreted nant cells in the circulation after liver transplantation.

cautiously in relation to HCC. We have conducted a study in which peripheral and central whole blood samples were taken at regular in-JAN N. M. IJZERMANS 1 tervals (immediately before surgery and 5, 30, 60, and DIRK-JAN BAC 2 120 minutes and 24 hours after recipient hepatectomy) BERT G. M. NIESTERS 3 from five consecutive patients undergoing liver trans-Departments of 1 Surgery, 2 Hepatology, and plantation for benign liver disease. Indications for liver


๐Ÿ“œ SIMILAR VOLUMES


Randomized controlled trial of pegylated
โœ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 246 KB ๐Ÿ‘ 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Treatment of chronic hepatitis C with in
โœ D M Simon; S C Gordon; M M Kaplan; R S Koff; F Regenstein; G Everson; Y M Lee; F ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 217 KB ๐Ÿ‘ 2 views

We studied the antiviral effectiveness and safety of interferon alfa-n3, a natural alpha interferon which contains multiple interferon species, in the treatment of previously untreated patients with chronic hepatitis C. Seventy-seven patients were randomized to receive either 1.0, 2.5, 5.0, or 10.0

Response to higher doses of interferon a
โœ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 193 KB ๐Ÿ‘ 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

A randomized controlled trial of high-do
โœ Di Marco, Vito; Lo Iacono, Oreste; Cammร , Calogero; Almasio, Piero L.; Vaccaro, ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 170 KB ๐Ÿ‘ 2 views

In chronic hepatitis C virus (HCV) infection, the rate of sustained response to interferon is low. We evaluated, in patients responding to a 26-week course of interferon, the effect of high-dose maintenance therapy in preventing relapse. Three hundred and ten patients with chronic HCV infection (38.

Lymphoblastoid interferon alfa-n1 improv
โœ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 122 KB ๐Ÿ‘ 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-โฃ) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l